2022 Revenues ($USD) : $50,545,000,000.00
2022 R&D spend : $9,996,000,000.00
2022 Number of Employees : 101,703
Fiscal Year End : 12/31/22
Leader : CEO Vas Narasimhan

Basel-based Novartis had a solid year in 2022, with Q4 sales increasing by 3% and full-year core operating income growth of 8%. Its Innovative Medicines division had a Q4 margin of 36.4% and a full-year margin of 36.9%. The company has been focusing on becoming a pure-play innovative medicines company, and with the planned spinoff of Sandoz, it aims to fully transition into this role, following similar recent moves by Pfizer, J&J and GSK. Novartis has guided to improved financials, with 4% sales growth and a core operating income margin goal of 40%. —BB